Wolverine Trading, LLC Biogen Inc. Put Options Transaction History

Wolverine Trading, LLC

$94.2 Billion
Q2 2024

Put Options

26 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	BUY	$190.52 - $236.72 $1.31 Million - $1.63 Million	6,900 Added 29.24%	30,500 $7.07 Million
Q1 2024 May 15, 2024	SELL	$212.02 - $267.71 $1.42 Million - $1.79 Million	-6,700 Reduced 22.11%	23,600 $5.09 Million
Q4 2023 Feb 14, 2024	SELL	$222.59 - $267.94 $779,065 - $937,790	-3,500 Reduced 10.36%	30,300 $7.84 Million
Q3 2023 Nov 15, 2023	BUY	$253.3 - $285.89 $2.68 Million - $3.03 Million	10,600 Added 45.69%	33,800 $8.69 Million
Q1 2023 May 15, 2023	SELL	$256.56 - $292.34 $9.49 Million - $10.8 Million	-37,000 Reduced 61.46%	23,200 $6.38 Million
Q4 2022 Feb 14, 2023	SELL	$252.44 - $306.72 $10.1 Million - $12.3 Million	-40,000 Reduced 39.92%	60,200 $16.7 Million
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $7.71 Million - $10.6 Million	39,600 Added 65.35%	100,200 $26.5 Million
Q2 2022 Aug 15, 2022	BUY	$187.54 - $223.02 $3.19 Million - $3.79 Million	17,000 Added 38.99%	60,600 $12.4 Million
Q1 2022 May 16, 2022	SELL	$193.77 - $244.14 $8.56 Million - $10.8 Million	-44,200 Reduced 50.34%	43,600 $9.2 Million
Q4 2021 Feb 14, 2022	BUY	$223.92 - $287.77 $2.02 Million - $2.59 Million	9,000 Added 11.42%	87,800 $21.1 Million
Q3 2021 Nov 12, 2021	SELL	$282.99 - $369.05 $11 Million - $14.4 Million	-38,900 Reduced 33.05%	78,800 $22.5 Million
Q2 2021 Aug 06, 2021	BUY	$259.0 - $414.71 $9.19 Million - $14.7 Million	35,500 Added 43.19%	117,700 $40.7 Million
Q1 2021 May 14, 2021	SELL	$242.95 - $284.63 $5.1 Million - $5.98 Million	-21,000 Reduced 20.35%	82,200 $22.7 Million
Q4 2020 Feb 12, 2021	BUY	$236.26 - $355.63 $4.06 Million - $6.12 Million	17,200 Added 20.0%	103,200 $25.1 Million
Q3 2020 Nov 13, 2020	BUY	$264.77 - $305.71 $1.56 Million - $1.8 Million	5,900 Added 7.37%	86,000 $24.3 Million
Q2 2020 Aug 13, 2020	SELL	$258.66 - $342.55 $1.86 Million - $2.47 Million	-7,200 Reduced 8.25%	80,100 $20.9 Million
Q1 2020 May 11, 2020	SELL	$268.85 - $341.04 $21.4 Million - $27.1 Million	-79,600 Reduced 47.69%	87,300 $27.6 Million
Q4 2019 Feb 12, 2020	BUY	$220.06 - $304.07 $22,006 - $30,407	100 Added 0.06%	166,900 $49.4 Million
Q3 2019 Nov 14, 2019	BUY	$217.44 - $243.88 $2.91 Million - $3.27 Million	13,400 Added 8.74%	166,800 $38.4 Million
Q2 2019 Aug 20, 2019	SELL	$219.29 - $241.72 $8.97 Million - $9.89 Million	-40,900 Reduced 21.05%	153,400 $35.9 Million
Q1 2019 May 15, 2019	BUY	$216.71 - $338.96 $12.3 Million - $19.2 Million	56,600 Added 41.1%	194,300 $45.9 Million
Q4 2018 Feb 14, 2019	SELL	$278.5 - $352.75 $4.48 Million - $5.68 Million	-16,100 Reduced 10.47%	137,700 $40.4 Million
Q3 2018 Nov 14, 2018	BUY	$293.51 - $383.83 $10.7 Million - $14 Million	36,400 Added 31.01%	153,800 $54.3 Million
Q1 2018 May 15, 2018	SELL	$260.13 - $367.91 $5.28 Million - $7.47 Million	-20,300 Reduced 14.74%	117,400 $32.1 Million
Q4 2017 Feb 14, 2018	BUY	$307.64 - $344.58 $15.7 Million - $17.6 Million	51,100 Added 59.01%	137,700 $43.9 Million
Q3 2017 Nov 15, 2017	BUY	$281.15 - $329.69 $24.3 Million - $28.6 Million	86,600	86,600 $27.1 Million

Others Institutions Holding BIIB

# of Institutions

1,018

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

Vanguard Group Inc Valley Forge, PA

16.6M
Shares

$2.88 Billion
0.08% of portfolio
Primecap Management CO Pasadena, CA

16.3M
Shares

$2.84 Billion
2.78% of portfolio
Black Rock Inc. New York, NY

14.5M
Shares

$2.53 Billion
0.08% of portfolio
State Street Corp Boston, MA

7.1M
Shares

$1.23 Billion
0.07% of portfolio
T. Rowe Price Investment Management, Inc. Baltimore, MD

5.68M
Shares

$987 Million
0.83% of portfolio

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.

Account